Emerging concepts in intestinal immune control of obesity-related metabolic disease

Nat Commun. 2021 May 10;12(1):2598. doi: 10.1038/s41467-021-22727-7.

Abstract

The intestinal immune system is an important modulator of glucose homeostasis and obesity-associated insulin resistance. Dietary factors, the intestinal microbiota and their metabolites shape intestinal immunity during obesity. The intestinal immune system in turn affects processes such as intestinal permeability, immune cell trafficking, and intestinal hormone availability, impacting systemic insulin resistance. Understanding these pathways might identify mechanisms underlying treatments for insulin resistance, such as metformin and bariatric surgery, or aid in developing new therapies and vaccination approaches. Here, we highlight evolving concepts centered on intestinal immunity, diet, and the microbiota to provide a working model of obesity-related metabolic disease.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • B-Lymphocytes / immunology
  • Cytokines / metabolism
  • Diet Therapy
  • Gastrointestinal Microbiome / immunology*
  • Humans
  • Immune System / cytology
  • Immune System / metabolism
  • Inflammation / immunology
  • Inflammation / metabolism
  • Insulin Resistance / immunology
  • Metabolic Diseases / immunology*
  • Metabolic Diseases / metabolism*
  • Metabolic Diseases / microbiology
  • Metabolic Diseases / therapy
  • Obesity / diet therapy
  • Obesity / immunology
  • Obesity / metabolism*
  • Obesity / therapy
  • T-Lymphocytes / immunology

Substances

  • Cytokines

Grants and funding